Corvus Pharmaceuticals, Inc. Debt Securities, Available-for-sale
Corvus Pharmaceuticals, Inc. (CRVS) had Debt Securities, Available-for-sale of $62.82 million as of 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2025-11-04
- 2025-09-30: Debt Securities, Available-for-sale $62.82M.
- 2025-06-30: Debt Securities, Available-for-sale $59.72M.
- 2025-03-31: Debt Securities, Available-for-sale $39.21M.
- 2024-12-31: Debt Securities, Available-for-sale $43.22M.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2025-09-30 | $62.82M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $59.72M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $39.21M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $43.22M 10-Q · filed 2025-11-04 |
| 2024-09-30 | $36.97M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $32.41M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $14.67M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $14.53M 10-K · filed 2025-03-25 |
| 2023-09-30 | $12.06M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $29.36M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $24.81M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $29.14M 10-K · filed 2024-03-19 |
| 2022-09-30 | $25.03M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $28.25M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $31.48M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $5.99M 10-K · filed 2023-03-28 |
| 2021-09-30 | $4.03M 10-Q · filed 2021-11-01 |
| 2021-06-30 | $7.54M 10-Q · filed 2021-08-02 |
| 2021-03-31 | $22.86M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $27.80M 10-K · filed 2022-03-10 |
| 2020-09-30 | $28.39M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $38.55M 10-Q · filed 2020-07-30 |
| 2020-03-31 | $45.21M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $72.83M 10-K · filed 2021-03-25 |
| 2019-09-30 | $77.35M 10-Q · filed 2019-10-29 |
| 2019-06-30 | $66.66M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $66.83M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $75.40M 10-K · filed 2020-03-09 |
| 2018-09-30 | $81.89M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $105.16M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $41.37M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $44.95M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |